Drugs / ISH0688
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07505043 | Mar 2026 → Feb 2027 expected | hypertriglyceridemia | SUNHO（China）BioPharmaceutical CO., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISH0688 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07505043 ↗ |
| Modality | Protein / enzyme biologic | “ISH0688 is a human IgG1 Fc-FGF21 fusion protein.” NCT07505043 ↗ |
| Route | Subcutaneous | “via subcutaneous injection” NCT07505043 ↗ |